Quick Answer
ZyVersa Therapeutics, Inc. reported Net Income Loss of -$24.95 million for the year ending 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -165.1% in Net Income Loss from 2024 to 2025.
- This data is from ZyVersa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2022 to 2025), ZyVersa Therapeutics, Inc.'s Net Income Loss has declined by 77.6%.
- Historical annual values: Fiscal year 2025: -$24.95 million | Fiscal year 2024: -$9.41 million | Fiscal year 2023: -$98.30 million | Fiscal year 2022: -$75.0 thousand | Fiscal year 2022: -$14.05 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: